As of Tuesday morning, the US Food and Drug Administration (FDA) had yet to make a decision on whether to approve vaccines for use in the United States for a new strain of measles, according to the FDA’s website.
According to a press release issued on Wednesday, “The FDA will consider a request from the United Kingdom to approve a vaccine for use as a first line treatment for children and adolescents with febrile measles virus (MMV).”
While the FDA does not make any decisions on whether vaccines will be approved for use, the agency has approved vaccines for children for the MMR vaccine and the DPT vaccine.
While the UK has a history of approving vaccine for children with febrillazine fever, a viral illness that is more common in the UK, the vaccines are expected to receive FDA approval in the US.
According the FDA, the UK’s approval of the vaccines will not affect the vaccine’s effectiveness in the country.
The FDA’s announcement does not provide a timetable for the approval of any vaccine.
It is not clear whether the UK will approve the vaccines as a single vaccine, as was the case with the DBS vaccine for measles in the 1980s, or in combination with other vaccines for the vaccine to be used in the vaccine.
According US news outlet Fox News, the FDA is considering the request for approval of a vaccine in the new strain.
In October, the European Medicines Agency (EMA) approved a measles vaccine for Europe, the first vaccine to have been approved in the continent.
The EMA approved the vaccine for the EEA in April.
The US Food & Drug Administration approved the MMR and DPT vaccines in April, the same month the UK approved the DTS vaccine.